91蜜桃视频

产物资料
  91蜜桃视频 >>> 产物目录 >>> **学 >>> 一抗

罢贰搁罢抗体

如果您对该产物感兴趣的话,可以
产物名称: 罢贰搁罢抗体
产物型号:
产物展商: XYbscience
产物文档: 无相关文档

简单介绍

罢贰搁罢抗体端粒酶在大多数真核生物染色体末端复制是一种逆转录酶必不可少的。拉长端粒。这是一种逆转录酶,通过在酶的RNA成分中复制一个模板序列,将简单的重复序列添加到染色体末端。罢贰搁罢抗体端粒酶与端粒酶的表达是近年来研究的学科由于其链接到细胞的永生化大DNA蛋白复合物。


罢贰搁罢抗体  的详细介绍
 

TERT抗体ICC, IHC严格验证,品质保证.适用于多种种属反应性,被多篇文献引用并有用户反馈信息.确保特异性!产物具有以下特点:

1、全:网络全世界的上等产物,基本上各种抗体产物在该公司均能找到

2、新:产物及网站更新非常快,基本上每周均有新产物出现

3、优:产物质量好,投诉比较少

4、强:强大的技术支持队伍和力量,网站上有齐全的技术资料以及客户评论,并提供实时在线技术咨询,使您使用产物时没有任何后顾之忧。

产物编号xy-1411R

英文名称罢贰搁罢

中文名称端粒酶逆转录酶抗体

别    名EST2; hEST2; TCS1; Telomerase associated protein 2; Telomerase Catalytic Subunit; Telomere Reverse Transcriptase; Telomerase reverse transcriptase; TERT; TP2; TRT; TERT_HUMAN; Telomerase reverse transcriptase; HEST2; Telomerase catalytic subunit; Telomerase-associated protein 2.  

JournalPMIDIFApplicationBiosensors & Bioelectronics (2013)Others5.4370OtherMolecular biology reports (2012)222378622.5060ICC

说 明 书50ul  100ul  200ul

研究领域肿瘤  细胞生物  **学  细胞凋亡  转录调节因子  

抗体来源搁补产产颈迟

克隆类型笔辞濒测肠濒辞苍补濒

TERT抗体交叉反应 Human, Mouse, Rat,

产物应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=3?g/Test IF=1:100-500 (石蜡切片需做抗原修复)

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

分 子 量124kDa

细胞定位细胞核 细胞浆

性    状Lyophilized or Liquid

浓    度1mg/1ml

免 疫 原KLH conjugated synthetic peptide derived from human TERT

亚    型IgG

纯化方法affinity purified by Protein A

储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

生 产 商BIOSS

PubMedPubMed

产物介绍产补肠办驳谤辞耻苍诲:

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. It elongates telomeres. It is a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Telomerase are large DNA-protein complexes with telomerase expression being the subject of recent research due to its link to cell immortalization. Recent evidence has shown that MYC upregulates the catalytic subunit of telomerase, TERT, and that Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by addition of the telomere repeat TTAGGG. The enzyme consists of a protein component with reverse transcriptase activity, encoded by this gene, and an RNA component which serves as a template for the telomere repeat. Telomerase expression plays a role in cellular senescence, as it is normally repressed in postnatal somatic cells resulting in progressive shortening of telomeres. Deregulation of telomerase expression in somatic cells may be involved in oncogenesis. Studies in mouse suggest that telomerase also participates in chromosomal repair, since de novo synthesis of telomere repeats may occur at double-stranded breaks. Alternatively spliced variants encoding different isoforms of telomerase reverse transcriptase have been identified; the full-length sequence of some variants has not been determined. Alternative splicing at this locus is thought to be one mechanism of regulation of telomerase activity. [provided by RefSeq, Jul 2008].


Function:

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.


Subunit:

Homodimer; dimerization is required to produce a functional complex. Oligomer; can form oligomers in the absence of the telomerase RNA template component (TERC). Catalytic subunit of the telomerase holoenzyme complex composed minimally of TERT and TERC. The telomerase complex is composed of TERT, DKC1, WDR79/TCAB1, NOP10, NHP2, GAR1, TEP1, EST1A, POT1 and a telomerase RNA template component (TERC). The molecular chaperone HSP90/P23 complex is required for correct assembly and stabilization of the active telomerase. Interacts directly with HSP90A and PTGES3. Interacts with HSPA1A; the interaction occurs in the absence of TERC and dissociates once the complex has formed. Interacts with RAN; the interaction promotes nuclear export of TERT. Interacts with XPO1. Interacts with PTPN11; the interaction retains TERT in the nucleus. Interacts with NCL (via RRM1 and C-terminal RRM4/Arg/Gly-rich domains); the interaction is important for nucleolar localization of TERT. Interacts with SMARCA4 (via the bromodomain); the interaction regulates Wnt-mediated signaling. Interacts with MCRS1 (isoform MCRS2); the interaction inhibits in vitro telomerase activity. Interacts with PIF1; the interaction has no effect on the elongation activity of TERT. Interacts with PML; the interaction recruits TERT to PML bodies and inhibits telomerase activity.


Subcellular Location:

Nucleus, nucleolus. Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm. Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.


Tissue Specificity:

Expressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T-lymphocytes, and at a low to undetectable level in peripheral blood T-lymphocytes.


Post-translational modifications:

Ubiquitinated, leading to proteasomal degradation.

Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation by the AKT pathway promotes nuclear location.


DISEASE:

Note=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.

Defects in TERT are associated with susceptibilty to aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.

Note=Genetic variations in TERT are associated with coronary artery disease (CAD).

Defects in TERT are the cause of dyskeratosis congenital autosomal dominant type 2 (DKCA2) [MIM:613989]. A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.

Defects in TERT are the cause of dyskeratosis congenital autosomal recessive type 4 (DKCB4) [MIM:613989]. A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.

Defects in TERT are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF) [MIM:178500]. Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease.


Similarity:

Belongs to the reverse transcriptase family. Telomerase subfamily.

Contains 1 reverse transcriptase domain.


SWISS:

O14746


Gene ID:

7015


抗体选择指南

TERT抗体检测任何目的靶蛋白都有不止一种抗体可供选择,为缩小抗体的选择范围选中合适的抗体,需要考虑如下几种因素:

1 分析或应用的类型

2)样本蛋白的结构性质

3)样本的种属

4)抗体宿主的种类

5)抗体的标记和检测

1 分析试验的应用类型一般抗体说明书都列出该抗体经试验验证过适用于何种分析类型,如:

可以应用于WB IHC ICC ELASA 分析等,如果抗体说明书没有提及的应用类型,并不意味着该抗体不适用于此种分析应用类型,而仅是说明尚未经过此种分析试验验证,如果抗体不适用某些分析试验,则会在抗体说明书上标注出来不适于某分析试验。

2 样本蛋白的结构性质了解样本蛋白的结构性质有助于选择*合适的抗体,至少需要考虑两方面因素

(1)..待测样本蛋白的结构域:TERT抗体是由各种不同**原**宿主而制备得来,其中的**原包括:全长蛋白、蛋白片断、多肽、全有机体(如:**)或细胞,抗体说明书一般都有**原的描述,如果打算检测的是蛋白片断或一种特殊的同型物或蛋白全长的某一区域,则必须选择用含此片段域的**原制备出的抗体。如果打算用FACS 流式检测活细胞的表面蛋白,则需要选择含该表面蛋白的胞外域来**制备的抗体。

(2)样本的提取或处理过程:某些抗体要求样本经过某些特殊处理,例如:许多抗体只识别还原和变性的、表位已暴露不受二级四级结构阻碍的蛋白样本,另一方面,某些抗体仅识别天然折迭状态的蛋白。

当选择**组化的抗体时,应注意某些抗体只识别未固定的冷冻的组织,而另一些抗体则适用于无需抗原修复解交联步聚的甲醛固定石蜡包埋的组织,这些都会在抗体说明书上应用部分标示出来 3 样本的物种 应选择物种相同或有交叉反应的抗体,抗体可能与不同物种的同种靶蛋白有交叉反应,因其氨基酸序列同源性较高。

如果样本的种类未列入抗体说明书上的交叉反应种属表中,并不意味着该抗体不适用于检测该物种的蛋白,而只是表示该物种尚未用此抗体检测验证过,应通过序列比对的方法来预测交叉反应,TERT抗体可应用Expasy NCBI BLAST 来进行不同物种蛋白同源性比对。

4 一抗宿主物种的选择一般说来,在使用偶联二抗结合无偶联物的一抗时,一抗宿主动物的物种选择较为重要,对于**组化而言,尽可能选择与样本不同种系物种的一抗,从而避免二抗与样本内源性**球蛋白产生交叉反应,

例如:检测小鼠样本蛋白,则不应选择小鼠或大鼠源的一抗,*好选兔源的一抗,则二抗则可选择偶联了检测分子(酶、荧光素、生物素等)的抗兔IgG。如果选择有偶联物的一抗则不适用上述情况,除**组化外的其它对不含内源性**球蛋白样本的检测方法,则抗体宿主物种的影响不大,如对不含IgG 的细胞裂解物样本的western blotting检测。

尽管如此,TERT抗体含有血清的组织裂解物和组织培养上清中含有**球蛋白,还原变性样本中含IgG,在western blot 检测中则结合出现IgG 分子50 and 25 kDa 的重链和轻链条带。

5 二抗的选择 二抗应选用与使用的一抗相同的物种来源,例如:如果你的一抗是小鼠的单克隆抗体,二抗则选抗小鼠的二抗anti-mouse secondary。建议检查二抗说明书确保该抗体适用于你的检测应用, 二抗一般连接荧光素FITC 或发光团。

6 双重染色抗体的选择用未偶联一抗进行细胞培养物或组织切片的双重**染色要求一抗来源于不同物种并且二抗分别识别其中之一,二抗说明书应描述其与其它物种来源的**球蛋有否有交叉吸附。

合格 PPP2R5D 蛋白质磷酸酶2调节亚基5D/PP2A-B56-δ抗体
合格 Phosphoserine/threonine 磷酸化丝氨酸/苏氨酸抗体
合格 CHRM4 毒蕈碱型乙酰胆碱受体M4抗体
合格 PAX1 配对盒基因1抗体
合格 phospho-SAPK3 (Thr183+Tyr185) 磷酸化丝裂原活化蛋白激酶磷酸酶p38γ抗体
合格 GLUR4 离子型谷氨酸受体4抗体
合格 Omgp 少突细胞髓磷脂糖蛋白抗体
合格 MGLUR3 代谢型谷氨酸受体-3抗体
合格 MGLUR1 + MGLUR5 促代谢型谷氨酸受体1+5抗体
合格 GPR18 G蛋白偶联受体18抗体
合格 GPR1 G蛋白偶联受体1抗体
合格 合格 PAX8 配对盒基因8抗体
合格 GPR125 G蛋白偶联受体125抗体
合格 GPR136 G蛋白偶联受体136抗体
合格 GPR126 G蛋白偶联受体126抗体
合格 GPRC5B G蛋白偶联受体C5B抗体
合格 TRADD 肿瘤坏死因子受体1相关死亡域蛋白抗体
合格 GRASP 一般受体磷酸肌醇相关支架蛋白1抗体
合格 GODZ 棕榈酰转移酶GODZ抗体
合格 Paralemmin 1 细胞膜调控蛋白Paralemmin 1抗体

产物留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键础濒迟+厂或颁迟谤濒+贰苍迟别谤发送信息!
2.如有必要,请您留下您的详细联系方式!